Source comparison
Comparison at a glance
Semaglutide (GLP-1 receptor agonist) Chronic weight management; roughly 10–15% body-weight reduction vs placebo in obesity RCTs Strong human RCT — approved medicine (marketed as Wegovy) Prescription drug; GI side effects; weight tends to return after stopping
This comparison does not assign a generated winner or score.
- Semaglutide (GLP-1 receptor agonist)
- Chronic weight management; roughly 10–15% body-weight reduction vs placebo in obesity RCTs
- Strong human RCT — approved medicine (marketed as Wegovy)
- Prescription drug; GI side effects; weight tends to return after stopping
- Tirzepatide (GIP/GLP-1 receptor agonist)
- Weight reduction; up to ~21% at 72 weeks in an obesity RCT
- Strong human RCT — approved medicine (marketed as Zepbound)
- Prescription drug; GI side effects; regain after discontinuation
- Tesamorelin (GHRH analog)
- Reducing visceral (deep abdominal) fat in HIV-associated lipodystrophy
- Strong human RCT — but narrow population and endpoint
- Approved only for HIV lipodystrophy, not general fat loss; visceral fat re-accumulates off-treatment
- AOD-9604 (human GH fragment)
- Lipolysis / fat breakdown
- Preclinical (rodent); human obesity trials never led to approval
- Not approved for obesity anywhere; prohibited in sport by WADA
- MOTS-c (mitochondrial-derived peptide)
- Glucose/fat metabolism; described as an “exercise mimetic”
- Preclinical / mechanistic; no human fat-loss trials
- Human data limited to observational exercise studies, not peptide administration